Mr. Daniel G. Welch is Executive Partner at Sofinnova Ventures, Inc., Independent Director at Hyperion Therapeutics, Inc., and Independent Director at Seattle Genetics, Inc.
He has over 30 years of experience across both multi-national pharmaceutical companies and biotech companies.
Mr. Welch joined Sofinnova Ventures in 2015. Most recently, he was the Chairman, CEO and President of InterMune. Beginning in 2003, he led a comprehensive company turn-around, refocusing the company’s development efforts.
He built the InterMune development and commercial teams that delivered the successful approval of Esbriet. In October 2014, Roche acquired InterMune. From August 2002 to January 2003, he served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., a pharmaceutical company. From October 2000 to June 2002, he served as president of the pharmaceutical division of Elan Corporation, PLC (acquired by Perrigo). From September 1987 to August 2000, he served in various senior management roles at Sanofi-Synthelabo (now Sanofi) and its predecessor companies Sanofi and Sterling Winthrop. During his time at Sanofi, he led the successful worldwide launches of Plavix, Eloxatin and Avapro as Vice President of Worldwide Marketing and he served as COO of the U.S. business. From November 1980 to September 1987, he was with American Critical Care, a division of American Hospital Supply.
Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina.